HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen

Origins of HIV-infected Leukocytes and Virions in Semen

(2014) L. Houzet et al.   JOURNAL OF INFECTIOUS DISEASES

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Xenobiotic transporter expression along the male genital tract

(2014) David M. Klein et al.   REPRODUCTIVE TOXICOLOGY

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

(2013) Mackenzie L. Cottrell et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

(2013) Stephen Weller et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing

(2013) Benjamin N. Greener et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002–2011 survey

(2012) Sidonie Lambert-Niclot et al.   AIDS

Single- and Multiple-Dose Pharmacokinetics of Darunavir Plus Ritonavir and Etravirine in Semen and Rectal Tissue of HIV-Negative Men

(2012) Kevin C. Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

HIV-1 RNA May Decline More Slowly in Semen than in Blood following Initiation of Efavirenz-Based Antiretroviral Therapy

(2012) Susan M. Graham et al.   PLoS One

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract

(2011) Laura J Else et al.   ANTIVIRAL THERAPY

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

(2011) Myron S. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission

(2011) J. M. Baeten et al.   Science Translational Medicine

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis

(2010) Deborah Donnell et al.   LANCET

Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV

(2010) Stephen Taylor et al.   Current Opinion in HIV and AIDS

HIV-1 Populations in Semen Arise through Multiple Mechanisms

(2010) Jeffrey A. Anderson et al.   PLoS Pathogens

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET